Abstracts tagged "interstitial lung disease and synthetase syndrome"

Abstract Number: 1908 • 2016 ACR/ARHP Annual Meeting
Identification of a Novel Pro-Inflammatory T Cell Epitope from His-tRNA-Synthetase Associated with Interstitial Lung Disease in Anti-Jo-1 Positive Patients
Angeles Shunashy Galindo-Feria¹, Inka Albrecht², Antonella Notarnicola², Maryam Dastmalchi², Anatoly Dubnovitsky³, Tatiana Sandalova³, Genadiy Kozhukh³, Lars Rönnblom⁴, Adnane Achour⁵, Vivianne Malmström⁶ and Ingrid E. Lundberg², ¹Department of Medicine., Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ²Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, ³Department of Medicine Solna and Department of Infectious Diseases,, Science for Life Laboratory, Karolinska Institutet and Karolinska University Hospital, Solna, Sweden, ⁴Uppsala University, Department of Medical Sciences, Rheumatology and Science for Life Laboratory, Uppsala, Sweden, ⁵Science for Life Laboratory, Department of Medicine Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, ⁶Department of Medicine, Rheumatology Unit, Department of Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: Previous studies have demonstrated that CD4+ T cells from peripheral blood of anti-histidyl-tRNA synthetase (anti-His-tRNA) also known as anti-Jo-1 positive patients proliferate in response…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].